Thus, given its unique insulin sensitising effect, a risk-benefit analysis of pioglitazone treatment in patients with T2DM is crucial for determining its place in the current and future glucose-lowering treatment algorithm. This evidence concerns the gene INS and type 2 diabetes mellitus.